Difamilast

Difamilast (OPA-15406) is a topical, selective and nonsteroidal phosphodiesterase-4 (PDE4) inhibitor with particularly efficient inhibition of subtype B (IC50=11.2 nM) . Difamilast can be used for the research of mild to moderate atopic dermatitis (AD) [1][2][3].

Product Specifications

CAS Number

[937782-05-3]

Product Name Alternative

OPA-15406

UNSPSC

12352005

Target

Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/difamilast.html

Purity

99.40

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(C)OC(C=C(C1=NC(CNC(C(C=CC=C2)=C2OCC)=O)=CO1)C=C3)=C3OC(F)F

Molecular Formula

C23H24F2N2O5

Molecular Weight

446.44

References & Citations

[1]Hanifin JM, et, al. OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD) : A phase-II randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2016 Aug;75 (2) :297-305.|[2]Ahluwalia J, et, al. Phosphodiesterase 4 Inhibitor Therapies for Atopic Dermatitis: Progress and Outlook. Drugs. 2017 Sep;77 (13) :1389-1397.|[3]Soeberdt M, et, al. Small molecule drugs for the treatment of pruritus in patients with atopic dermatitis. Eur J Pharmacol. 2020 Aug 15;881:173242.